| Literature DB >> 15523367 |
Abstract
Three patients with refractory pemphigus vulgaris improved after rituximab, an anti-CD20 monoclonal antibody directed against B cells. Treatment was well tolerated immediately, but one patient developed fatal pneumocystis carinii pneumonia. Serious infections have occurred in several pemphigus patients treated with rituximab and immunosuppressive medications, warranting further evaluation of risk-benefit ratio.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15523367 DOI： 10.1016/j.jaad.2004.06.007
Source DB: PubMed Journal: J Am Acad Dermatol ISSN： 0190-9622 Impact factor: 11.527